British Columbia started to cover the cost of cholinesterase inhibitors (ChEIs)-donepezil, galantamine, and rivastigmine-for patients with mild to moderate dementia and prominent Alzheimer's disease. Objectives: To examine the impact of this policy on persistence with ChEIs. Methods: A populationbased cohort study was conducted using British Columbia administrative health data. We examined 45,537 new ChEI users aged 40 years and older between 2001 and 2012; 20,360 (45%) started the treatment after the coverage policy was launched. Patients were followed until treatment discontinuation, defined as a ChEI-free gap of 90 days, death, or December 2013. Persistence on ChEIs was estimated using survival analysis and competing risk approach. Hazards of discontinuation were compared using competing risk Cox regression with propensity adjustment. Results: Patients who started ChEI therapy after the introduction of the coverage policy had a significantly longer persistence. Median ChEI persistence until discontinuation or death was 9.37 months (95% confidence interval [CI] 9.0-39.7) and 17.6 months (95% CI 16.9-18.3) in patients who started therapy before and after the new policy, respectively. The propensity-adjusted hazard ratio for discontinuing therapy was 0.91 (95% CI 0.88-0.94). Similar patterns were observed for persistence with the first ChEI (propensity-adjusted hazard ratio of 0.94; 95% CI 0.91-0.98). In rivastigmine users, the hazard ratio was insignificant (0.98; 95% CI 0.92-1.02). Conclusions: The British Columbia ChEI coverage policy was associated with significantly prolonged persistence with donepezil and galantamine, but not rivastigmine.
Introduction
In October 2007, the British Columbia public drug insurance plan, PharmaCare, initiated coverage of three cholinesterase inhibitors (ChEIs) used in Alzheimer's disease: donepezil, rivastigmine, and galantamine [1] . ChEIs were previously not covered by PharmaCare because clinical trials had not adequately addressed the effects on day-to-day function but rather focused on the effects on cognitive abilities [2] . To address this perceived evidence gap, ChEI coverage was provided as part of a research program using the coverage with evidence development concept [3] . The combined coverage-research program, known as the Alzheimer's Drug Therapy Initiative (ADTI), was designed to address gaps in knowledge on safety, effectiveness, and appropriate use of ChEIs.
The new ADTI program provided coverage to patients who demonstrated mild to moderate cognitive decline and Alzheimer's disease or other dementia with prominent Alzheimer's disease [4] . Mild to moderate cognitive decline was defined as a score of 10 to 26 on the Standardized Mini-Mental State Examination and 4 to 6 on the Global Deterioration Scale. Patients underwent reassessment every 6 to 7 months. Patients lost their eligibility for reimbursement if the score on the Standardized Mini-Mental State Examination was lower than 10 or the score on the Global Deterioration Scale was higher than 6 or lower than 4. Memantine, another medication marketed for Alzheimer's disease, was not covered because it works by a different mechanism of action and has a different indication (moderate to severe dementia). Furthermore, evidence on memantine's effectiveness was considered to be insufficient to justify drug coverage [5] . The new ChEI coverage policy was implemented subject to costsharing levels that were part of the larger PharmaCare plan; ChEI users had to share prescription costs in a manner that depended on family income and the total annual cost of their medications [6] .
Included in the ADTI research program were several assessments of the impact of drug coverage on health service utilization. Because the new drug coverage policy started about 10 years after the first ChEI, donepezil, was licensed in Canada [7] , it was possible to compare utilization before and after its implementation. This study examined ChEI persistence, a common measure of drug utilization, which is defined as the time from drug initiation to discontinuation [8] . Lack of efficacy and harmful events are the most common causes of drug discontinuation [9] ; cost, however, is also a factor [10] [11] [12] . Given the new coverage policy introduced criteria for ChEI discontinuation, we hypothesized that it led to shorter persistence, despite the decrease in out-of-pocket fees. The goal of this study was to examine the effect of new ChEI coverage policy on persistence and risk of discontinuing ChEIs in the Canadian province of British Columbia.
Methods

Data Source and Study Cohort
We conducted a population-based cohort study, using data from the British Columbia Ministry of Health administrative claim databases. We analyzed data on prescription dispensing, demographic characteristics, enrollment in the provincial Medical Service Plan, fee-for-service payments to physicians and alternative providers, and hospital separations. Data were linked using de-identified unique patient numbers. The study protocol was approved by the Clinical Research Ethics Board, University of British Columbia, and the Human Research Ethics Board, University of Victoria.
We identified new users of donepezil, galantamine, or rivastigmine between January 1, 2001, and December 31, 2012. We excluded patients with a pharmacy refill for any ChEI in the year before entering the cohort, as well as those without continuous enrollment in the provincial health program for at least 1 year. Patients younger than 40 years at cohort entry and those with combination therapies, defined as refills of two or more different ChEIs at cohort entry, were also excluded. Patients were included as new users only once. They were followed until the earliest occurrence of December 31, 2013, or a gap of more than 14 days in continuous provincial health plan enrollment. Patients without a diagnosis of Alzheimer's disease and those in long-term care facilities were not excluded, but these factors were controlled for in the adjusted analysis.
Outcomes
We analyzed two types of outcomes: ChEI persistence, measured until discontinuation of any ChEI, and persistence with the first ChEI. For ChEI persistence, we extracted the ChEI refill records of the study cohort. We aggregated refills on the same date and selected the largest days-supply recorded regardless of the specific ChEI dispensed. Days supplied in each refill were limited to 90 because a very large number of days could mean an error in recording. ChEI discontinuation was defined as a failure to refill any ChEI prescription within 90 days of the exhaustion of the medication supply in earlier refills (i.e., 90-day ChEI-free gap). We allowed stockpiling of not more than 90 days and adjusted the dispensing date to the end of the previously days-supply dispensed. Stockpiling was managed this way because new prescriptions occasionally preceded the exhaustion of drug supply from earlier prescriptions. The end of course was the date of exhaustion of the refilled ChEI or the end of follow-up data, whichever was earliest. Three mutually exclusive events determined the latest "on-treatment" date: 1) discontinuation, when the ChEI-free gap ended before the end of follow-up data; 2) death, when the patient died before the end of the ChEI-free gap; or 3) censoring, when follow-up data ended before discontinuation or death. ChEI persistence was measured from cohort entry until discontinuation, death, censoring, or end of refilled days, whichever was the earliest.
In a subsequent analysis of persistence with only the first ChEI, switching between ChEI was considered discontinuation. Switching was defined as the first pharmacy refill of a second ChEI during treatment or before the end of the ChEI-free gap, and patients who added a second ChEI (combination therapy) were also considered "switchers." For switchers, the end of course was set to the switching date or the exhaustion of the first ChEI, whichever was earlier.
Exposure, Covariates, and Possible Confounders
We compared two groups of ChEI new users. Prepolicy new users were patients who entered the cohort before November 1, 2007, and postpolicy new users were patients who entered the cohort after this date. In multivariate regression analyses we controlled for demographic characteristics and proxies for clinical factors that may have confounded the association between the policy exposure and the persistence outcome (see Table S1 in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2016.03. 1832). We controlled for age, sex, income, geographical residence, Alzheimer's diagnosis, and disease duration, as well as long-term care residence, comorbidities (Romano score [13, 14] ), and number of physician visits, hospital days, and different generic drugs refilled in the year before cohort entry. In addition, the models included a series of dichotomous variables to indicate the use of statins, antipsychotics, anxiolytics, hypnotics, antidepressants, and nonsteroidal anti-inflammatory drugs in the year before cohort entry. We also adjusted for prescriber specialty and the first drug prescribed (donepezil, galantamine, or rivastigmine). We did not control for combination therapy with memantine at cohort entry because less than 1% of the patients had a dispensing of memantine within the 3 months before cohort entry.
To further reduce bias and improve the validity of our comparison estimates, we calculated high-dimensional propensity scores (HDPSs) [15, 16] for ChEI discontinuation within the first 3 years of treatment. We used data from the year before the entry date. The HDPS method searches through all variables in a database to identify and adjust for those unanticipated variables that may confound the main analysis. The method is described in detail elsewhere [15] . The HDPS included all the aforementioned variables in addition to the 200 variables that were captured by the HDPS algorithm. A large separation of the HDPS distributions between the comparison groups was found (c-statistics 0.960), meaning that the prepolicy and postpolicy new users were very different. We trimmed approximately 10% of the new users who had extreme, nonoverlapping scores [17] . This trimming allowed us to include in the analysis only those patients who had the potential to be treated both before and after the new coverage policy, and therefore to increase the validity relative risk estimates. The remaining 45,537 patients constituted the study cohort.
Statistical Analysis
Persistence, or time to discontinuation, was estimated and compared using survival analysis, and death, which was frequent in the study cohort, was approached as a competing risk [18] . In this study, death and discontinuation are not independent events because discontinuation required the patient to be alive at least 90 days after the exhaustion of the refilled drug. We undertook a three-phase approach. First, we considered either
discontinuation or death as an outcome of interest. Persistence, herein defined as time until discontinuation or death, was estimated using product-limit Kaplan-Meier methodology, and hazards were compared using Cox proportional hazard regression. These estimates are important in managing drug coverage plans; the cause of end of treatment-either discontinuation or death-is of secondary importance. Second, we calculated the crude cumulative incidence for discontinuation approaching death as a competing risk, using Gray's methods and the SAS CIF macro (SAS software, Cary, NC, USA) [19] [20] [21] . Finally, on the basis of the Cox proportional hazards model, we conducted competing risk regression to estimate the effect of predictors on the subhazard function [22] , as described in detail elsewhere [23] .
Additional Analyses
Several additional analyses were conducted to further explore the robustness of our results. First, to test whether the policy effect varied with different ChEIs (effect modification), we included interaction terms for the first ChEI and policy in the model. Next, we explored the effect of varying the length of the ChEI-free gap on the relative persistence estimates (hazard ratios); ChEI-free gaps of 30 days, 60 days, and 120 days were used [24] [25] [26] . Finally, we explored the association between the new policy and persistence in three different populations: patients aged 65 years and older, patients with Alzheimer's disease, and "severe cases." Patients with Alzheimer's disease were identified on the basis of at least one diagnosis of Alzheimer's disease and related dementia in the year before treatment on the basis of the International Classification of Diseases, Ninth Revision codes (290, 294, 331, or 797). "Severe cases" were patients who fulfilled at least three of the following criteria: 1) top third of number of physician visits, 2) top third of hospital days, 3) top third of Romano scores, 4) top third of number of drugs dispensed, 5) longest third of disease duration, and 6) dispensing records from at least two of the following therapeutic groups: antipsychotics, anxiolytics, hypnotics, and antidepressants.
Results
Study Cohort
We identified 51,455 ChEI new users between January 2001 and December 2012. After trimming on the basis of the propensity distribution, 45,537 patients were included in the final study cohort (Fig. 1) . Mean age was 79.5 Ϯ 8.2 years, 95% were 65 years or older, and 60% were women. Most of the new users (55%) were diagnosed with Alzheimer's disease or related dementia in the year before cohort entry. Donepezil, galantamine, and rivastigmine were used by 66%, 20%, and 14% of the patients, respectively. Postpolicy new users, that is, ChEI users who started treatment after the new drug coverage policy was launched, made up 45% of the study cohort (20,360 patients), including 39%, 52%, and 60% of donepezil, galantamine, and rivastigmine new users, respectively. Postpolicy new users were older, sicker, and earned a lower income. Baseline characteristics are presented in Table 1 . Sixty-four percent of the patients had followup available for longer than 2 years and 30% for longer than 5 years. As expected, longer follow-up was available for prepolicy new users (Table 1) .
ChEI Persistence
A total of 30,257 discontinuations of ChEI treatment were observed, and an additional 8,394 patients died while being treated or before the end of the ChEI-free gap. Within a year after ChEI initiation, overall 45% of the new users discontinued therapy and an additional 5.0% died while on treatment: 62% and 5.7% in prepolicy new users compared with 31% and 4.5% in postpolicy new users, respectively. ChEI persistence, defined as time until death or discontinuation, ranged from 1 day to almost 13 years, with a crude median product-limit estimate of 12.3 months (95% confidence interval 12.0-12.6). In comparison, persistence in all 51,455 ChEI new users, including patients excluded on the basis of the propensity distribution, was 12.8 months (95% confidence interval 12.5-13.1). In the study cohort, estimated persistence in postpolicy new users was significantly longer than that in prepolicy new users (median of 17.6 and 9.3 months; Table 2 , Fig. 2 in black) . The hazard for ChEI discontinuation or death decreased by 7% in new users who started ChEI treatment after the new drug coverage policy was launched. We plotted the hazard for discontinuation or death for the study cohort over time (see Fig. S1 in Supplemental Materials found at http://dx.doi. org/10.1016/j.jval.2016.03.1832) and found the highest hazard for therapy discontinuation soon after treatment was started. This hazard decreased until plateauing around year 2. Hazard for death, in contrast, gradually increased over time. In competing risk analysis, the cumulative incidence for ChEI discontinuation was significantly lower in postpolicy new users (Fig. 3 in black) : 50% of the prepolicy and postpolicy new users discontinued ChEI treatment after 11.9 and 29.8 months, respectively ( Table 2 ). The hazard for discontinuation was lower in postpolicy new users by 9% compared with patients who started treatment before the new coverage policy.
Persistence with the First ChEI
A total of 32,436 patients discontinued the first ChEI during the follow-up, and an additional 7,365 patients died while being treated or before the end of the ChEI-free gap. A year after ChEI initiation, 49% of the new users discontinued the first drug and an additional 4.8% died. Of those who discontinued, 12,675 (28%) did so within the first 3 months of use (38% and 19% of prepolicy and postpolicy new users, respectively) and 17,288 (38%) within the first 6 months of use (52% and 27% of prepolicy and postpolicy new users, respectively). Of patients who did not die on treatment, 49% were still using the drug after 1 year. Median persistence with first drug was shorter than overall ChEI persistence: 9.8 months compared with 12.3 months from treatment initiation until discontinuation or death (Table 2) . Overall, the relative estimates for first ChEI were similar to those for any ChEI. Longer persistence with the first ChEI was noticed in postpolicy users compared with prepolicy users (median 12.8 and 8.0 months; Table 2 , Fig. 2 in gray) . The hazard for discontinuation of first ChEI or death decreased by 5% after the new drug coverage was launched.
In competing risk analysis, 50% of the prepolicy and postpolicy new users experienced discontinuation of the first ChEI within 9.9 and 18.6 months, respectively (Table 2, Fig. 3 in gray) . Half of the postpolicy new users discontinued the first ChEI within 18.6 months and any ChEI within 29.8 months. This difference was larger than a 2-month difference observed in prepolicy new users and could be explained by an increase in switching frequency. The hazard for discontinuation was lower in postpolicy new users by 6% compared with patients who started treatment before the new coverage policy.
Additional Analyses
The individual ChEI was an effect modifier. The association between the policy and discontinuation was insignificant in rivastigmine new users, but the hazard significantly decreased by 6% to 7% in postpolicy new users of donepezil and galantamine (Table 3 ). In the analysis of rivastigmine users with a V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 6 8 8 -6 9 6 diagnosis of Alzheimer's disease and related dementia in the year before cohort entry, we estimated crude and propensity-adjusted hazard ratios for discontinuation of 0.92 (0.84-1.01) and 0.92 (0.84-1.02) comparing postpolicy with prepolicy new users. Nevertheless, the power to detect a hazard ratio of 0.92 was insufficient in this setting (power of 0.67). Noticeably, postpolicy new users were 18-fold more likely to have refills of rivastigmine patches compared with prepolicy new users; 62% and 3.3% of rivastigmine refills in postpolicy and prepolicy new users, respectively, were of patches.
Neither methods nor population had a significant effect on the hazard ratio estimates. Increasing lengths of the ChEI-free gap used to define discontinuation (30, 60 , and 120 days) resulted in robust estimates, with hazard ratios significantly smaller than 1, that is, decrease in discontinuation risk in postpolicy new users compared with prepolicy new users ( Table 3 ). The hazard ratios were also robust in subcohorts of patients aged 65 years and older, severe cases, and patients with Alzheimer's disease and related dementia (Table 3 ). In these three cohorts, the hazard ratios were smaller (away from the null) or similar to the ratio estimated in the study cohort.
Discussion
The new ChEI coverage policy in British Columbia was associated with significantly prolonged persistence. The association was robust regardless of patients' population (age, Alzheimer's diagnosis, or disease severity) or the length of ChEI-free gap used to define discontinuation. The association observed did not support our hypothesis that the new policy would shorten persistence because of the restrictive coverage criteria [4] . Longer persistence could result from decreased out-of-pocket fees, which has been shown to be a predictor associated with persistence in studies of other diseases [10] [11] [12] . Alternatively, longer persistence may be the result of improved selection of patients or improved care; the new policy not only specified clinical criteria for covering treatment, but also required regular follow-up every 6 months to reassess the patients before coverage could be renewed. Improved care may also have been the consequence of engaging physicians in dementia education programs, such as the province-wide "Dementia Education Strategy" [27, 28] . This study estimated population effect of the new policy rather than the effect on individuals. We analyzed populationbased data of ChEI new users in British Columbia and included patients regardless of their eligibility for drug coverage. Only 55% of the patients had a diagnosis of Alzheimer's disease or related dementia in the year before treatment, and 66% any time before treatment was started. We observed smaller (further away from the null) hazard ratios when we restricted the analysis to patients with a diagnosis of Alzheimer's disease or related dementia in the year before treatment. This result suggests that the postpolicy prolonged persistence in our main analysis was likely diluted by the inclusion of patients without Alzheimer's disease for whom public coverage was not an option. Furthermore, postpolicy new users were older and sicker compared with prepolicy new users, making them more sensitive to negative drug effects, which should have resulted in shorter persistence. Estimating a significant effect in spite of both circumstances increases the confidence that the drug coverage policy was associated with longer persistence in eligible patients (i.e., the direction of the "bias" is toward the null).
Persistence estimated in this study (median 9.8 months for first ChEI) and other cohort studies was shorter than expected on the basis of published randomized and open-labeled trials [25] . In three randomized clinical trials (RCTs), 33% of donepezil Note. Cumulative incidence of discontinuation was estimated using Fine and Gray's methodology [17, 19] . The incidence of discontinuation is the probability of experiencing discontinuing a small time interval conditional on the individuals both survived (i.e., did not die) and persist (i.e., did not discontinue) all previous intervals. The cumulative incidence is defined as the sum of the incidence in this interval and all previous time intervals [40] . ChEI, cholinesterase inhibitor; CI, confidence interval; HDPS, high-dimensional propensity score. * Crude hazard ratios included only the coverage policy as a variable in the model. Adjusted hazard ratios were estimated in models that also included the first ChEI prescribed as well as demographic characteristics, clinical status, and drug variables. HDPS-adjusted hazard ratios were estimated in models that consisted of policy (yes/no), age categories, sex, first drug prescribed (donepezil, galantamine, or rivastigmine), and quintiles of HDPS. Fig. 2 -Kaplan-Meier product-limit plots: persistence until discontinuation or death in ChEI new users. ChEI, cholinesterase inhibitor.
initiators discontinued treatment within 48 to 54 weeks [29] . This difference in discontinuation risk is probably due to dissimilarity between real-world patients and participants in RCTs of dementia [30] . Furthermore, participants in RCTs are generally more compliant than real-world patients [31] . The coverage policy did not affect persistence with rivastigmine. We did not expect the policy to have a variable impact on the different ChEIs. One explanation for the absence of postpolicy prolongation of persistence with rivastigmine was the introduction of a new rivastigmine product part way through the ADTI. The rivastigmine patch was approved for marketing by Health Canada in December 2007 [32] and covered by British Columbia PharmaCare starting in April 2009 [33] . Considering that patients were grouped on the basis of time of treatment initiation, we are unable to differentiate between the coincident effects of new coverage and a new product. The observed null estimates may reflect shorter persistence with the patch. The persistence with the rivastigmine patch, however, was suggested to be longer because of less gastrointestinal adverse effects and ease of use [34] [35] [36] [37] [38] . In the absence of studies comparing persistence in new users of the two rivastigmine products, further research is warranted. Alternatively, the null estimates of association Note. Numbers are hazard ratios (95% confidence interval), unless otherwise specified. Patients who started ChEI when coverage was available were compared with patients who started treatment earlier (i.e., prepolicy new users). Hazard ratios were estimated using Cox proportional hazard regression, accounting for death as a competing risk [19, 20] . ChEI, cholinesterase inhibitor; HDPS, high-dimensional propensity score. * HDPS-adjusted hazard ratios were estimated in models that consisted of age categories, sex, first drug prescribed (donepezil, galantamine, or rivastigmine), and quintiles of HDPS. † Hazard ratios were estimated from the full study cohort. The models also included interaction terms for policy (pre/post) and drug (donepezil/galantamine/rivastigmine). ‡ Drug-free gaps of increasing lengths were used to identify discontinuation. H 1 9 ( 2 0 1 6 ) 6 8 8 -6 9 6 between the policy and rivastigmine persistence could be the expression of "dilution" of the effect. In Canada, rivastigmine is the only ChEI indicated also for Parkinson's disease dementia, but these patients were not covered under the new policy. In the analysis of patients diagnosed with Alzheimer's disease, we did not have sufficient power to detect a difference between prepolicy and postpolicy rivastigmine new users, but the point estimate of 0.92 was similar to those estimated with other drugs.
This study had several limitations. First, on the basis of the nature of administrative data, the presence of a pharmacy refill claim for ChEIs did not guarantee that patients used the medication, and patients could discontinue a drug at any time during the refill period. The effect of these unknown factors would have led us to overestimate persistence, but this bias was likely similar for all comparison groups. In addition, the prolonged study period (2001-2013) with groups separated over time (prepolicy or postpolicy) and the use of real-life data increased the likelihood of additional changes that could have influenced persistence in the study population: changes to disease coding (moving from International Classification of Diseases, Ninth Revision to International Classification of Diseases, Tenth Revision in the hospital data [39] ), adding new diagnosis codes (British Columbia chronic diseases management program [40] ), and the introduction of new products that contain the same generic chemical.
The Canadian health care system is based on the principles of public administration, comprehensiveness, universality, portability, and accessibility. These high ideals are in constant competition with the fiscal reality of scarce financial resources. It is therefore important that new policies be evaluated for positive and negative effects. The timing of ChEI coverage change in British Columbia, almost a decade after these drugs were first introduced, allowed for the examination of the effect of the policy on drug utilization. Other provinces started covering ChEIs earlier: Ontario in 1999, Saskatchewan in 2000, and Quebec in 2000; persistence studies using data from these provinces did not examine the effect of coverage [25, 41, 42] . The competing risk approach used in this study is an additional strength. In survival analysis, right censoring is based on the assumption that censored patients experience the event of interest sometime after the end of follow-up. Right censoring at death is inappropriate because discontinuation is conditional on being alive, meaning that patients who died would never experience discontinuation. Failure to address competing events may introduce bias when the study population has high rates of this event. In the context of this study, 18.5% of the patients died while on treatment with ChEIs, and therefore competing risk is a significant source of bias.
Conclusions
A new drug coverage policy for ChEIs in British Columbia (ADTI) was associated with prolonged persistence on treatment with donepezil and galantamine, but not rivastigmine. Improved persistence could have been the result of a decrease in out-ofpocket fees because of public coverage and possibly improved patient selection. The prolonged persistence was robust to the methods used to define discontinuation and in different subpopulations. The results did not support the hypothesis that the implementation of discontinuation criteria for ChEI coverage would be associated with shorter persistence.
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